KGF Results Timeline: What Studies Measured, and When

What a "KGF timeline" refers to in the published literature

Keratinocyte growth factor (KGF, also known as fibroblast growth factor 7) is an epithelial-specific growth factor. The research literature on KGF and its recombinant relatives was not built around personal week-by-week experience reports. It was built around defined measurement windows: the moments at which investigators drew blood, scored a tissue, photographed a scalp, or recorded a clinical event. A "timeline" question, translated into research terms, becomes: at which timepoints did researchers measure, and what did they report at those timepoints?

That reframing matters because the same molecule appears in very different research settings with very different clocks. Pharmacokinetic work runs on hours. Transplant and mucositis-prevention work runs on the days surrounding conditioning chemotherapy. Hair-related work runs on weeks, because follicle biology cycles slowly. None of these windows was designed to tell a reader when something would happen to them.

Hours: what pharmacokinetic work measured

The shortest timepoints in KGF-family research are pharmacologic. A 2002 report characterised the pharmacologic and pharmacokinetic profile of repifermin (KGF-2) in monkeys alongside comparative pharmacokinetics in humans (PMID 12102617), meaning that the study's sampling schedule was built around plasma disposition after administration rather than around any cosmetic or symptomatic endpoint. Researchers working at that scale were asking how a recombinant growth factor is distributed and cleared, not whether a visible change had occurred.

This distinction is the single most common source of confusion in timeline discussions. Circulating exposure to a protein can be brief while the downstream tissue biology it engages — epithelial proliferation, differentiation, barrier restoration — plays out over a much longer period. A short pharmacokinetic profile is not evidence of a fast outcome, and it is not evidence of a slow one either; the two measurements answer different questions. The repifermin work described above sat firmly in the first category (PMID 12102617).

Days to weeks: transplant and mucositis measurement windows

The most substantial human data on a recombinant KGF comes from oncology supportive care. A phase 1/2 study examined high-dose palifermin for graft-versus-host disease prophylaxis in patients undergoing HLA-matched unrelated donor haematopoietic cell transplantation (PMID 40331908). In that design, the intervention was positioned as prophylaxis — administered in relation to the transplant schedule, with outcomes accruing afterwards. The relevant clock in such trials is the transplant calendar itself, not a self-assessed sense of improvement.

A 2021 clinical practice guideline update addressed the prevention of oral and oropharyngeal mucositis in paediatric cancer and haematopoietic stem cell transplant patients (PMID 34252760). The framing of that guideline is explicitly preventive rather than reactive: interventions are considered in advance of predictable mucosal injury, and endpoints are scored during and after the treatment that causes the injury. For anyone trying to build a mental timeline, the implication is that KGF-class agents in this field were studied as pre-emptive measures tied to a known insult, not as open-ended therapies whose effects were tracked week by week in healthy people (PMID 34252760).

Weeks: hair-related measurement windows

Hair research imposes its own clock. Follicles cycle slowly through growth and rest phases, so studies in this area rarely place meaningful endpoints in the first days. A nonrandomized clinical trial investigated a keratinocyte growth factor hair serum for the prevention of chemotherapy-induced alopecia (PMID 41834767). As with the transplant literature, the design was preventive — the comparison point is the hair loss expected from chemotherapy, and the measurement window is anchored to treatment cycles rather than to an arbitrary "week 4, week 8, week 12" schedule.

Two design features of that trial matter for timeline interpretation. First, the study was nonrandomized (PMID 41834767), which limits how confidently any change over time can be attributed to the serum rather than to patient selection or to the natural course of treatment. Second, prevention trials report on what did not happen, which is a different kind of finding from a visible improvement at a given week.

Broader reviews place KGF within a crowded field. A narrative review of regenerative medicine strategies for hair growth and regeneration surveyed the range of approaches under investigation (PMID 36382136), and a 2024 review compared the therapeutic efficacies, phytochemical components and modulatory targets of plant extracts studied for hair loss prevention or hair growth (PMID 38792149). Reviews of this type describe what has been tried and what mechanisms were proposed; they do not supply a per-compound schedule of when effects appear.

Preclinical hair timelines, clearly labelled

Rodent hair studies illustrate the weeks-scale windows typical of this field, though the compounds tested are often unrelated to KGF. A 2025 study examined the effect of topically applied simvastatin plus luteolin on the development of hair in male mice (PMID 41075208) — a different intervention entirely, included here only to show that murine hair-growth work is structured around repeated topical application and later assessment rather than immediate observation. Mouse hair cycles do not map onto human hair cycles, and a preclinical timeline should never be read as a human one.

Hours to days: preclinical acute-injury timelines

KGF also appears in acute-injury models, where the measurement window collapses to hours and days. A 2025 study reported that mesenchymal stem cell-secreted KGF ameliorated acute lung injury via the Gab1/ERK/NF-κB signalling axis (PMID 40640718). Acute lung injury models are, by definition, short: the insult is delivered, and tissue and signalling readouts follow within a compressed period. Researchers in that work were characterising a mechanism, not establishing a dosing schedule for any human condition (PMID 40640718).

Measurement windows at a glance

Where the human timeline data is thin — explicitly

It should be stated plainly: there is no body of controlled human research that tracks KGF against standardised cosmetic or performance endpoints at 4, 8 and 12 weeks. The human evidence in the set reviewed here is confined to oncology supportive care, where a phase 1/2 study examined high-dose palifermin for GVHD prophylaxis in unrelated donor transplantation (PMID 40331908) and a nonrandomized trial examined a KGF hair serum for the prevention of chemotherapy-induced alopecia (PMID 41834767). Guideline-level work in the mucositis space is similarly disease-specific (PMID 34252760).

Everything faster than that comes from pharmacokinetics (PMID 12102617) or from animal mechanistic work (PMID 40640718), and those timescales describe molecules and models, not people. Reviews of the hair-growth field describe a landscape of candidate strategies rather than validated per-week expectations (PMID 36382136, PMID 38792149).

Safety and tolerability across the measurement window: What Studies Report

Phase 1/2 designs exist in part to characterise tolerability, and the high-dose palifermin study in HLA-matched unrelated donor transplantation was conducted in that framework (PMID 40331908). The nonrandomized KGF hair serum trial was likewise a clinical investigation in patients receiving chemotherapy (PMID 41834767), a population already under close medical monitoring. Because the verified literature summarised on this page does not enumerate specific adverse-event rates in a form that can be reproduced accurately, none are invented here; readers seeking event-level detail should consult the primary publications and a clinician.

A general principle from the earlier pharmacology work is also relevant to any tolerability discussion: the profile of a recombinant growth factor was characterised across species before clinical expectations were set (PMID 12102617), and animal exposure does not translate directly to human exposure.

Reading timeline claims critically

• Ask which clock a claim uses. Hours of plasma exposure (PMID 12102617) and weeks of hair-cycle observation (PMID 41834767) are not interchangeable.
• Ask whether the endpoint was prevention or improvement. Both the transplant study (PMID 40331908) and the hair serum trial (PMID 41834767) were framed around preventing an expected harm.
• Ask whether the design permits attribution. A nonrandomized trial reported changes over time without the comparison structure of a randomized study (PMID 41834767).
• Ask whether the subject was human. Mechanistic acute lung injury work (PMID 40640718) and murine topical hair work (PMID 41075208) are preclinical.

Readers looking for background on what KGF is, how it signals, and where recombinant forms have been studied can consult PeptideU's KGF overview in the Learn section, which covers mechanism and regulatory context rather than timelines.

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. Nothing above describes a protocol, a schedule, or an expected outcome for any individual; it summarises what the cited studies measured and when.

References

• Pharmacologic and pharmacokinetic profile of repifermin (KGF-2) in monkeys and comparative pharmacokinetics in humans (AAPS PharmSci, 2002)
• Phase 1/2 study of high-dose palifermin for GVHD prophylaxis in patients undergoing HLA-matched unrelated donor HCT (Blood, 2025)
• Clinical practice guideline for the prevention of oral and oropharyngeal mucositis in pediatric cancer and hematopoietic stem cell transplant patients: 2021 update (European Journal of Cancer, 2021)
• A Nonrandomized Clinical Trial Investigating Keratinocyte Growth Factor-Hair Serum for the Prevention of Chemotherapy-Induced Alopecia (Journal of Cosmetic Dermatology, 2026)
• Mesenchymal stem cell-secreted KGF ameliorates acute lung injury via the Gab1/ERK/NF-κB signaling axis (Cellular & Molecular Biology Letters, 2025)
• Regenerative medicine strategies for hair growth and regeneration: A narrative review of literature (Regenerative Therapy, 2022)
• Can Plant Extracts Help Prevent Hair Loss or Promote Hair Growth? A Review Comparing Their Therapeutic Efficacies, Phytochemical Components, and Modulatory Targets (Molecules, 2024)
• Effect of topically applied simvastatin plus Luteolin on enhancing the development of hair in male mice (Wiadomosci Lekarskie, 2025)